Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
NCT ID: NCT05097664
Last Updated: 2021-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2021-08-23
2022-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Demographic
2. Past medical/habitual history
3. COVID-19 status and related risk factors
4. Mucormycosis status and related risk factors
5. Ocular examination and imaging
6. Follow-up
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient, or legal representative opposing the pursuit of the research
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Ahvaz Jundishapur University of Medical Sciences
OTHER
Iran University of Medical Sciences
OTHER
Mashhad University of Medical Sciences
OTHER
Tabriz University of Medical Sciences
OTHER
Guilan University of Medical Sciences
OTHER
Kermanshah University of Medical Sciences
OTHER
Shahid Beheshti University of Medical Sciences
OTHER
Semnan University of Medical Sciences
OTHER
Isfahan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohsen Pourazizi
Dr. Mohsen Pourazizi
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohsen Pourazizi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Isfahan Eye Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Isfahan University of Medical Sciences
Isfahan, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mohsen Pourazizi
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Eshraghi B, Khademi B, Bahmani Kashkouli M, Khataminia G, Kiarudi MY, Nabie R, Abounoori M, Chaibakhsh S, Ghahvehchian H, Rastegarnasab F, Parandin M, Zia Z, Karamirad S, Jafarpour S, Fakoor M, Varshochi M, Mirmohammadkhani M, Ramezani-Majd A, Janipour M, Mahdian Rad A, Shekarchian F, Manouchehri V, Sajjadi SMJ, Etezad Razavi M, Khosropour H, Forouhari A, Ebrahimi F, Pourazizi M. One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study. Mycopathologia. 2025 Jul 6;190(4):63. doi: 10.1007/s11046-025-00966-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IR.MUI.MED.REC.1400.572
Identifier Type: -
Identifier Source: org_study_id